Clinical Trial Update: A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating disitamab vedotin in combination with radiotherapy as adjuvant treatment for HER2-overexpressing upper urinary tract urothelial carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Urinary Tract Urothelial Carcinoma

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)

Snippet

Sponsor: Peking University First Hospital | Conditions: Upper Urinary Tract Urothelial Carcinoma | Phase 2 | Status: RECRUITING